{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T16:09:48Z","timestamp":1778256588503,"version":"3.51.4"},"reference-count":52,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["R01 DA059822"],"award-info":[{"award-number":["R01 DA059822"]}],"id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["R01 DA144740"],"award-info":[{"award-number":["R01 DA144740"]}],"id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007281","name":"National Drug and Alcohol Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>To measure the proportion of women in New South Wales, Australia, retained in opioid agonist treatment (OAT) for opioid dependence (OD) during pregnancy and examine how this varies according to treatment and maternal characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort study using linked population\u2010based data, including OAT records, perinatal, hospital admissions, mental health outpatient services and criminal justice data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>New South Wales, Australia, January 2004\u2013December 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Pregnancies resulting in childbirth among women receiving OAT during pregnancy. The cohort included 4472 pregnancies among 2821 women receiving OAT during pregnancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements<\/jats:title>\n                    <jats:p>We defined retention as continuous receipt of OAT from the date of OAT initiation during pregnancy or date of conception (whichever came last) until childbirth. We calculated the proportion of women retained in treatment and 95% confidence intervals (CI) overall, by timing of initiation (pre\u2010conception, first, second and third trimester) and medication type (methadone, buprenorphine) at initiation. We used logistic regression to assess retention variation according to maternal socio\u2010demographic and clinical factors, including morbidities commonly co\u2010occurring with OD, stratified by timing of initiation. Data on dosing, other substance use and psychopharmacological medications were unavailable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>\n                      OAT was initiated pre\u2010conception in 74.8% (3346) of pregnancies, during the first trimester in 11.1% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009497), second trimester in 8.8% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009394) and third trimester in 5.3% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009237). Overall, women were retained in OAT for 84.3% (3771) of all pregnancies. Retention was 87.4% (95% CI = 86.3\u201388.6) with pre\u2010conception initiation; 65.8% (95% CI = 61.6\u201370.0) in the first trimester; 80.5% (95% CI = 76.5\u201384.4) second trimester; and 85.2% (95% CI = 80.8\u201389.7) third trimester. Retention was 72.4% (95% CI = 69.5\u201375.3) with buprenorphine and 87.7% (95% CI = 86.6\u201388.9) with methadone. Pregnancies delivered during 2019\u20132021 were less likely to be retained in treatment compared with those delivered during 2004\u20132006, regardless of the timing of initiation [pre\u2010conception initiation odds ratio (OR) = 0.49, 95% CI = 0.30\u20130.79; first trimester initiation OR = 0.29, 95% CI = 0.08\u20131.07; second\/third trimester initiation OR = 0.29, 95% CI = 0.10\u20130.91). Among women who initiated OAT pre\u2010conception, retention was lower among those whose first antenatal visit occurred after 20 gestational weeks (OR = 0.68, 95% CI = 0.53\u20130.86), those in their first (OR = 0.72, 95% CI = 0.54\u20130.97) or second pregnancy (OR = 0.73, 95% CI = 0.56\u20130.96) and those who initiated on buprenorphine (OR = 0.31, 95% CI = 0.24\u20130.40) or in a custodial setting (OR = 0.66, 95% CI = 0.44\u20131.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In New South Wales, Australia, from 2004 to 2021, over 84% of women receiving opioid agonist treatment during pregnancy were retained in treatment until childbirth; however, lower retention in later study years and among women initiating buprenorphine, coupled with recent guidelines recommending buprenorphine as first\u2010line therapy during pregnancy, highlights the need for ongoing monitoring and targeted support to improve retention among women who are at higher risk of discontinuation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/add.70325","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T02:23:28Z","timestamp":1768962208000},"page":"1520-1529","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Retention in opioid agonist treatment during pregnancy and variations according to treatment and maternal characteristics"],"prefix":"10.1111","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0611-6018","authenticated-orcid":false,"given":"Bianca","family":"Varney","sequence":"first","affiliation":[{"name":"National Drug and Alcohol Research Centre, Faculty of Medicine and Health UNSW Sydney  Sydney Australia"},{"name":"Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine and Health UNSW Sydney  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Jones","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, Faculty of Medicine and Health UNSW Sydney  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9778-0386","authenticated-orcid":false,"given":"Chrianna","family":"Bharat","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, Faculty of Medicine and Health UNSW Sydney  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3065-7495","authenticated-orcid":false,"given":"Jonathan","family":"Brett","sequence":"additional","affiliation":[{"name":"Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine and Health UNSW Sydney  Sydney Australia"},{"name":"St Vincent's Hospital Clinical School  Darlinghurst Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8513-2218","authenticated-orcid":false,"given":"Louisa","family":"Degenhardt","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, Faculty of Medicine and Health UNSW Sydney  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7799-3771","authenticated-orcid":false,"given":"Ju\u2010Lee","family":"Oei","sequence":"additional","affiliation":[{"name":"Department of Newborn Care The Royal Hospital for Women  Randwick Australia"},{"name":"School of Women's and Children's Health, Faculty of Medicine and Health UNSW Sydney  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sallie\u2010Anne","family":"Pearson","sequence":"additional","affiliation":[{"name":"Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine and Health UNSW Sydney  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6563-8804","authenticated-orcid":false,"given":"Alys","family":"Havard","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, Faculty of Medicine and Health UNSW Sydney  Sydney Australia"},{"name":"Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine and Health UNSW Sydney  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duong T.","family":"Tran","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, Faculty of Medicine and Health UNSW Sydney  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0273-8"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ogc.2014.02.005"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jmwh.12619"},{"key":"e_1_2_10_5_1","first-page":"713","article-title":"Managing opioid dependence in pregnancy","volume":"42","year":"2013","journal-title":"Aus J Gen Prac"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2007.10.007"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2008.02283.x"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15582"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15514"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1071\/PY22269"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.05.010"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12834"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2015.05.002"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.01.013"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139942"},{"key":"e_1_2_10_16_1","volume-title":"Substance use in pregnancy","author":"Prince MK","year":"2024"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(23)00095-0"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2022.2083174"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.02.012"},{"key":"e_1_2_10_20_1","first-page":"2018","volume-title":"NSW Clinical Guidelines: Treatment of Opioid Dependence","author":"NSW Ministry of Health","year":"2018"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2006.01651.x"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyaf037"},{"key":"e_1_2_10_23_1","volume-title":"National Opioid Pharmacotherapy Statistics Annual Data Collection (NOPSAD) 2025","author":"Australian Institute of Health and Welfare","year":"2025"},{"key":"e_1_2_10_24_1","unstructured":"Australian Bureau of Statistics.Births Australia.2022. Available from:https:\/\/www.abs.gov.au\/statistics\/people\/population\/births-australia"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108464"},{"key":"e_1_2_10_26_1","volume-title":"National Guidelines for Medication\u2010Assisted Treatment of Opioid Dependence","author":"Gowing L","year":"2014"},{"key":"e_1_2_10_27_1","volume-title":"Australian Product Information: Buvidal\u00ae weekly (buprenorphine) solution for injection","year":"2018"},{"key":"e_1_2_10_28_1","volume-title":"StatPearls","author":"Dydyk AM","year":"2024"},{"key":"e_1_2_10_29_1","volume-title":"Australian Product Information: Sublocade (Buprenorphine)","year":"2019"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003692"},{"key":"e_1_2_10_31_1","volume-title":"NDARC technical report: real\u2010world dosing intervals of long\u2010acting buprenorphine for opioid agonist treatment","author":"Chidwick K","year":"2023"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104255"},{"key":"e_1_2_10_33_1","unstructured":"Australian Bureau of Statistics.Census of Population and Housing: Socio\u2010Economic Indexes for Areas (SEIFA) Australia. [Available fromhttps:\/\/www.abs.gov.au\/websitedbs\/censushome.nsf\/home\/seifa2011] (accessed 17 March 2025)."},{"key":"e_1_2_10_34_1","unstructured":"Australian Centre for Housing Research.Accessibility\/Remoteness Index of Australia (ARIA +).2016. [Available fromhttps:\/\/able.adelaide.edu.au\/housing-research\/data-gateway\/aria] (accessed 17 March 2025)."},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.109091"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108647"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232086"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/03630242.2019.1610829"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2017.06.005"},{"key":"e_1_2_10_40_1","first-page":"221","volume-title":"Proceedings of the 5th Berkeley symposium on mathematical statistics and probability","author":"Huber PJ","year":"1967"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.2307\/1912526"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14453"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2019.305379"},{"key":"e_1_2_10_44_1","unstructured":"Schmidt R A(2024)Opioid agonist therapy during pregnancy: a feminist community\u2010engaged mixed methods study (Doctoral dissertation University of Toronto [Canada])."},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1005359"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2016.1100960"},{"key":"e_1_2_10_47_1","volume-title":"Clinical guidance for the Management of Substance use in pregnancy, Birth and the Postnatal Period","author":"NSW Health","year":"2024"},{"key":"e_1_2_10_48_1","volume-title":"Opioid Use Disorder and Treatment Among Pregnant and Postpartum Medicaid Enrollees","author":"Roberts T","year":"2023"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000002235"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.5334\/ijic.s3141"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108420"},{"key":"e_1_2_10_52_1","doi-asserted-by":"crossref","unstructured":"Tran D. Varney B. Jones N. Bharat C. Brett J. Oei J. et al. (2025).Trends in opioid agonist treatment for opioid dependence during pregnancy: a population\u2010based study in New South Wales 2005\u20132021. The Australasian Epidemiological Association Conference 16\u201318 July 2025 Hobart Tasmania Australia.","DOI":"10.1111\/dar.70139"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jogc.2023.05.012"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.70325","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/add.70325","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.70325","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:13:24Z","timestamp":1778253204000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/add.70325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1111\/add.70325"],"URL":"https:\/\/doi.org\/10.1111\/add.70325","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"2025-05-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}